根据名称进行药物检索

Ketoconazole 与 Xanax

Ketoconazole 与 Xanax互相作用以及同时服用的可能性。

检测结果:

Ketoconazole <> Xanax

现实性: 22.07.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用药物和阿普唑仑是不建议。使用这些药物在一起可能导致昏睡和缓慢的呼吸。重要的是，你告诉你的医疗保健提供者有关的所有其他药物的使用，包括维生素和草药。不停止使用药物而不谈论你的医生第一次。

医界专家:

禁忌:共同给予与康唑或药物可能会大大增加的等离子浓度和药理作用的苯并二氮杂卓的主要代谢通过CYP450 3A4. 该机制是生物利用度增加和/或减少清关，由于抑制的肠和肝CYP450 3A4由唑抗真菌剂。药物动力学研究、康唑(200毫克/天)和药物(400毫克/天)单独增加的高峰等离子浓度(C)、区域浓度时间曲线(AUC)和清除半衰期(T1/2)的一个单一的0.25毫克的剂量口服三唑仑由超过3,22和6倍，分别比安慰剂。同样，C，AUC和T1/2的一个单一的7.5毫克的剂量口服咪达唑仑分别超过3,-10和高3倍，分别在共同给予的康唑或药物相对于安慰剂。在哥伦比亚联合自卫军的一个2毫克IV剂量的咪达唑仑增加了5倍后的预处理与酮康唑。结果，对阿普唑仑已经较少戏剧性，大概是由于有限的一次通过新陈代谢的肠。在独立的研究，itraconazole和药物增加的哥伦比亚联合自卫军的阿普唑仑(0.8和1毫克单剂量口服)通过2.5-4倍，分别比安慰剂，同时，C不是受到明显的影响。药效有关的变化的相互作用包括增加和长期的镇静，增强苯并二氮杂卓有关的脑电图的效果，并且增加了受损的精神运动性能。相互作用受到高度interpatient的可变性。

管理：伴随使用的康唑或药物与阿普唑仑、口服咪达唑仑和三唑仑被认为是禁忌。氟康唑和咪康唑弱抑制剂的CYP450 3A4但仍然可能引起的相互作用，而萘芬不是一种抑制剂的CYP450 3A4和已经显示出没有任何效果的药物动力学的咪达唑仑和三唑仑. 或者，苯并二氮杂卓的不是代谢通过CYP450 3A4(例如，劳拉西泮、奥沙西泮,替马西泮)可以被认为是在患者需要康唑或酮康唑。

来源

Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ "The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin." Eur J Clin Pharmacol 54 (1998): 53-8
Wrighton SA, Ring BJ "Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine." Pharm Res 11 (1994): 921-4
Neuvonen PJ, Varhe A, Olkkola KT "The effect of ingestion time interval on the interaction between itraconazole and triazolam." Clin Pharmacol Ther 60 (1996): 326-31
Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ "Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole." Clin Pharmacol Ther 66 (1999): 461-71
Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI "Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents." J Clin Pharmacol 36 (1996): 783-91
"Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
Vonmoltke LL, Greenblatt DJ, Cotreaubibbo MM, Harmatz JS, Shader RI "Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine." Br J Clin Pharmacol 38 (1994): 23-31
"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
Brown MW, Maldonado AL, Meredith CG, Speeg KV "Effect of ketoconazole on hepatic oxidative drug metabolism." Clin Pharmacol Ther 37 (1985): 290-7
Greenblatt DJ, Vonmoltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI, Wright CE "Interaction of triazolam and ketoconazole." Lancet 345 (1995): 191
"Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.
Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K "Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam." Psychopharmacology 139 (1998): 269-73
Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI "Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences." Clin Pharmacol Ther 64 (1998): 237-47
Ahonen J, Olkkola KT, Neuvonen PJ "Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam." Ther Drug Monit 18 (1996): 124-7
"Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
Varhe A, Olkkola KT, Neuvonen PJ "Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole." Clin Pharmacol Ther 56 (1994): 601-7
Olkkola KT, Backman JT, Neuvonen PJ "Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole." Clin Pharmacol Ther 55 (1994): 481-5
Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2
Varhe A, Olkkola KT, Neuvonen PJ "Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism." Br J Clin Pharmacol 41 (1996): 319-23